Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 10,525 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Not applicable Interventional

OR Video-Laryngoscope Evaluations

NCT07888946
View directory record Official record
Conditions
Video Laryngoscopy, Quality Improvement, Operating Rooms, Comparative Effectiveness Study, Survey
Interventions
AMBU Product, CMAC-Storz, Glidescope
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Soup and Bread Recipe Impacts on Ingestive Behavior

NCT07146958
View directory record Official record
Conditions
Obesity &Amp; Overweight
Interventions
Chia seeds, Hemp seeds, Placebo
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting No phase listed Observational

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyposis
Interventions
DUPIXENT®
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

NCT03604978
View directory record Official record
Conditions
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions
Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

NCT00077285
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, carboplatin, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting No phase listed Observational

Study for Remote Investigation of Evaporative Dry Eye Disease

NCT06976515
View directory record Official record
Conditions
Evaporative Loss Dry Eye Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional Results available

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

NCT02648997
View directory record Official record
Conditions
Meningiomas
Interventions
Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, External Beam RT, Nivolumab - 1 mg/kg, Ipilimumab - 3 mg/kg
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 1 Interventional

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

NCT03081910
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

NCT04784247
View directory record Official record
Conditions
Advanced Sarcoma
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Not applicable Interventional

Multiple Sclerosis Falls Insight Track

NCT05837949
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MS FIT: Falls Insight Track
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 3 Interventional

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793
View directory record Official record
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

NCT04576104
View directory record Official record
Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
Interventions
Biopsy Procedure, Extended Release Metformin Hydrochloride, Megestrol Acetate, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting No phase listed Observational

Perform® Humeral System - Fracture Study (PFX)

NCT05773352
View directory record Official record
Conditions
Traumatic Arthropathy of Shoulder, Fracture Humerus, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains
Interventions
Tornier Perform® Humeral System - Fracture
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rancho Mirage, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

NCT03995147
View directory record Official record
Conditions
B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Interventions
Pembrolizumab, R-CHOP Protocol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 1 Interventional

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

NCT03709758
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Daunorubicin, Cytarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 1 Interventional

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

NCT05101148
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Rochester, Minnesota • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118
View directory record Official record
Conditions
Prostatic Cancer, Castration-Resistant
Interventions
JSB462, AAA617
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT06087458
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
Interventions
VOY-101
Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • Poway, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Phase 2 Interventional

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Placebo, Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
14
States / cities
Mesa, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting Not applicable Interventional

Implementing an Adolescent and Young Adult (AYA) mHealth Vaping Cessation Program Into Oncology Clinics

NCT05967585
View directory record Official record
Conditions
Vaping, Vaping Cessation
Interventions
Behavioral: Quitting Program (TIQ)
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
13 Years to 24 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 9, 2026, 10:19 AM EST
Active, not recruiting No phase listed Observational

Sepsis Associated Encephalopathy (SAE) Biomarkers

NCT03133208
View directory record Official record
Conditions
Sepsis, Altered Mental Status, Sepsis-Associated Delirium, Sepsis Associated Encephalopathy, Delirium, Sepsis Associated
Interventions
Blood draws
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 9, 2026, 10:19 AM EST